IL-1 Beta Beckons In Type 2 Diabetes and Potentially, Cardiovascular Disease
This article was originally published in Start Up
Executive Summary
The IL-1 receptor has long been a target for autoimmune therapies. Now, data are emerging using several drugs, notably IL-1 beta antibodies, which support the general notion that blocking the IL-1 pathway could be useful in treating diabetes, particularly in patients at risk of cardiovascular disease. Indeed, one recent paper suggests that it could even be a therapeutic strategy to prevent heart failure after acute AMI.